A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

NCT02510781 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Epirubicin
DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Carboplatin

Sponsor

Hospital Affiliated to Military Medical Science, Beijing